<DOC>
	<DOC>NCT00298987</DOC>
	<brief_summary>The purpose of this clinical research study is to provide dasatinib treatment to patients with advanced chronic myelogenous leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who no longer can tolerate treatment with imatinib. The safety of the treatment will also be studied.</brief_summary>
	<brief_title>A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Diagnosis of accelerated phase or blast phase CML or Ph+ ALL Intolerant or resistant to imatinib mesylate 18 years of age or older ECOG performance 02 (greater than 50% of time out of bed) Adequate liver and kidney function Pregnant or breastfeeding females History of significant cardiac disease History of significant bleeding disorder (not CML) Prisoners</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Chronic Myeloid Leukemia Accelerated and Blast Phase</keyword>
	<keyword>Leukemia, Acute, Philadelphia-Positive</keyword>
</DOC>